Abstract: Plasma concentrations of the stable endothelin-1 precursor, C-terminal portion of the endothelin-1 precursor, determined prospectively in 293 newborn infants (gestational age, 24-41 weeks) at birth and on day 3 of life were unrelated to gestational age at birth, but strongly associated with respiratory distress when measured on day 3 of life.
Introduction 38
Endothelin-1 is secreted by endothelial cells and acts as a potent vasoconstrictor (1). 39
Raised plasma concentrations of endothelin-1 have been related to respiratory 40 morbidity (1), including respiratory distress syndrome in newborn infants (2) (3) (4) (5) . 41
Whereas endothelin-1 is unstable and therefore unsuited for diagnostic use, its 42 secretion can be estimated by measuring CT-proET-1, the C-terminal portion of the 43 endothelin-1 precursor (6, 7). The objective of this prospective study was to 44 investigate the association between levels of circulating CT-proET-1 at birth and on 45 day 3 of life and perinatal morbidity in preterm and term infants. 46
47

Subjects and methods 48
This cross-sectional study was performed between March 2009 and December 2010, 49 enrolling a total of 293 infants born at the University Hospitals of Basel and Zürich, 50 both Switzerland, after written informed parental consent. The Ethics Committees of 51
Basel and Zürich approved the study protocol. 52
Blood samples were drawn from 256 umbilical veins at the time of delivery, with 53 additional 83 paired samples from the umbilical artery and 90 paired blood samples 54 from postnatal day 3. Samples were also taken from 37 unrelated infants on 55 postnatal day 3 only. Blood sampling and processing as well as collection of clinical 56 data have been described previously (8 
Results
69
Baseline characteristics of infants enrolled, split by gestational age (preterm vs. 70 term), are shown in Table 1 . 71
At birth, CT-proET-1 concentrations were unrelated to birth weight (BW) and 72 gestational age (GA) (Fig 1A) . Venous umbilical cord CT-proET-1 concentrations 73 were consistently higher than matched arterial ones (M 148 vs. 134 pmol/L, 74 p<0.001), but both values were closely related (R S =0.745, p<0.001, n=83). 75
Umbilical cord CT-proET-1 concentrations (n=256) were slightly increased in infants 76 with compromized placental perfusion (M 156 vs. 142 pmol/L, p=0.015, n=137) and 77 infants born to mothers with preeclampsia (M 163 vs. 144 pmol/L, p=0.032, n=256). 78
Delivery mode or signs of fetal distress immediately before birth (low arterial umbilical 79 cord pH, suspect fetal heart tracing) and infections (i.e. maternal signs of infection at 80 delivery, histologically proven chorioamnionitis, and neonatal bloodstream-proven
In contrast to CT-proET-1 at birth, CT-proET-1 on day 3 of life was inversely related 83 to BW (R S -0.610) and GA (R S -0.649) (n=127, p<0.001) (Fig 1B) , due to a profound 84 postnatal increase in CT-proET-1 concentrations in preterm infants with respiratory 85 morbidity. When investigating the association between CT-proET-1 and respiratory 86 morbidity in preterm infants, we found that days of mechanical ventilation, continuous 87 positive airway pressure (CPAP), and oxygen supplementation correlated each with 88 CT-proET-1 level on day 3 (R S 0.566, 0.658, and 0.819, respectively, for all p<0.001). 89
Increasing levels of respiratory support in the first 3 days of life (none, CPAP only, 90 endotracheal ventilation) were associated with increasing circulating concentrations 91 of CT-proET-1 concentrations on day 3 ( Figure 1C ). A very similar association was 92 found between degree of respiratory distress syndrome (radiological diagnosis) and 93
CT-proET-1 concentrations on day 3 ( Figure 1D) . This study demonstrates that CT-proET-1 concentrations in umbilical cord blood at 105 birth are unaffected by GA (Fig 1A) . Compromized placental perfusion appears to be 106 associated with slightly elevated CT-proET-1 concentrations at birth. CT-proET-1 107 concentrations rose strongly from birth to day 3 of life in infants with RDS but not 108 infants without respiratory disease (Fig 1C) . Moreover, CT-proET-1 on day 3 of life 109 was associated with radiological degree of RDS suggesting a dose-response 110 relationship (Fig 1D) . CT-proET-1, however, was not predictive of BPD after adjusting 111 for GA. 112
An early increase in endothelin-1 has been shown to be a prognostic factor for BPD 113 when endothelin-1 in tracheal aspirate was measured on day 7 of life (9). In our 114 study, plasma CT-proET-1 concentrations were measured on day 3 of life which may 115 reduce prognostic power compared to measurement on day 7. Moreover, we cannot 116 exclude a type 2 error given that only 11 infants who had CT-proET-1 measurements 117 on day 3 were diagnosed with mild BPD and 6 with moderate/severe BPD. It remains 118 nevertheless intriguing to speculate that determining plasma CT-proET-1 within the 119 first week of life may help to identify infants at risk of BPD. Functional data on 120 endothelin-1 action (10) denote that endothelin-1 is not only a marker but a mediator 121 of respiratory disease in newborn infants. These insights provide the framework for 122 further studies investigating endothelin-1 action in newborn infants compromised by 123 respiratory distress. 
